# Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

> **NCT02323269** · — · TERMINATED · sponsor: **Biogen** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting
- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT02323269
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** 109MS415 ImPROve study was terminated due to patient enrollment challenges and feasibility . The decision was not a result of safety concerns.
- **Last updated:** 2016-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323269, "Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02323269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*